Press Releases

– Data provide additional evidence supporting development of praliciguat as a potential treatment for diabetic nephropathy and for heart failure with preserved ejection fraction – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 23, 2018-- Ironwood Pharmaceuticals, Inc.

– Program Designed to Support U.S. Regulatory Filing of IW-3718 as Potential Treatment for Patients Who Continue to Suffer From GERD Despite Receiving Standard of Care – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 21, 2018-- Ironwood Pharmaceuticals, Inc.

- Praliciguat Phase IIa data to be featured in an oral presentation - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 20, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced that the company will present clinical and preclinical data for the company’s

– Olinciguat Phase II trial in sickle cell disease continues to enroll patients – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 7, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Orphan

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 6, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13 th , 2018 at 4:00 p.m. Pacific Time ( 7:00 p.m.

– Also Evidence of Efficacy in Persistent GERD Patients with Erosive Esophagitis – – Additional Data Presented Further Highlight Role of Bile Acid in Persistent GERD – – Ironwood Expects to Advance IW-3718 into Phase III Trials in 3Q 2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun.

Ironwood Shareholders Re-Elect All Three Ironwood Director Nominees CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 31, 2018-- Ironwood Pharmaceuticals , Inc. (NASDAQ: IRWD), a commercial biotech company, today announced that, based on the vote count following the 2018 Annual Meeting of Shareholders,

-  IW-3718 Phase IIb Data Selected for the Distinguished Abstract Plenary Session - CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 23, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced that the company in collaboration with researchers will present

- Urges Shareholders to Vote "FOR" the Ironwood Director Nominees on the WHITE Proxy Card - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a commercial biotech company, today announced that it has mailed a letter to shareholders highlighting the experience and

- Board Urges Shareholders to Vote "FOR" all Three of Ironwood's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced that it filed an investor

CAMBRIDGE, Mass. & DUBLIN--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc.  (NASDAQ: IRWD) and Allergan plc  (NYSE: AGN) announced today that the companies have reached an agreement with Aurobindo Pharma Ltd., resolving patent litigation brought in response to Aurobindo Pharma's abbreviated new

- Urges Shareholders to Vote "FOR" the Ironwood Director Nominees on the WHITE Proxy Card - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced that it filed definitive proxy materials with the Securities and Exchange

-- AboutYourGut.com Provides Resources and Education Focused on Irritable Bowel Syndrome with Diarrhea (IBS-D), Irritable Bowel Syndrome with Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC) --

- Separation designed to unlock value, increase operational performance and strategic flexibility, and tailor capital structure for each business - - Separation expected to result in two independent, publicly traded companies - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc.

– First quarter revenue increased 33% year-over-year to $69 million , driven primarily by LINZESS ® (linaclotide) U.S. net sales of $159 million and commercial margin of 63% – – IW-3718 Phase III program expected to initiate in the third quarter of 2018 – – Phase II sGC programs, praliciguat and

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 17, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its first quarter 2018 investor update conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, May 1, 2018 . Individuals interested in participating in the call

- Advises Shareholders That No Action Is Required at This Time - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced that it has received notice from Sarissa Capital Management LP ("Sarissa") that it intends to nominate

CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present corporate updates at two upcoming investor conferences in March: 2018 Cowen and Company 38th Annual Health Care Conference on Monday, March 12, 2018 at 11:20 a.m.